Cabergoline
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Cabergoline
- Pharmacist Assessment Report
- Cabergoline: Dopamine agonist → progeria-short stature-pigmented nevi syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cabergoline: Dopamine agonist → progeria-short stature-pigmented nevi syndrome
One-Sentence Summary
Cabergoline is a dopamine receptor agonist that is currently marketed in Canada. The TxGNN model predicts it may be relevant to progeria-short stature-pigmented nevi syndrome, with a score of 0.9906. No clinical trials and no publications currently support this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | progeria-short stature-pigmented nevi syndrome |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for cabergoline is not available in the data compiled for this report. Cabergoline is generally known as a dopamine D2 receptor agonist.
No mechanistic rationale connecting dopamine D2 agonism to progeria-short stature-pigmented nevi syndrome could be identified from the available data. The high TxGNN score (0.9906) is a computational model output and is not supported by any trial or publication. The prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Three single-ingredient cabergoline products hold valid licences in Canada. Indication text and dosage forms are not recorded in the local data.
| DIN | Product Name |
|---|---|
| 02455897 | APO-CABERGOLINE |
| 02549611 | JAMP CABERGOLINE |
| 02242471 | DOSTINEX |
Safety Considerations
- Drug Interactions: 60 interacting drugs were identified. The main ones are:
- Major: lorcaserin and clarithromycin.
- Moderate: metoclopramide.
- The remaining interactions are of unclassified severity, for example with pantoprazole, omeprazole, metformin, prednisone and simvastatin.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction has no supporting clinical trials or publications, and no plausible mechanistic link could be identified. The evidence level is L5, so there is no basis to advance it.
To proceed, the following is needed:
- A documented biological rationale linking dopaminergic signalling to this syndrome
- Any preclinical or clinical studies, or case reports, in this condition
- Mechanism-of-action data for cabergoline from a curated source
- Package insert warnings and contraindications from Health Canada for safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.